NRX Pharmaceuticals, Inc.NRXPEarnings & Financial Report
Nasdaq
NRXP Q3 2025 Key Financial Metrics
Revenue
$242.0K
Gross Profit
$145.0K
Operating Profit
$-4.0M
Net Profit
$-5.9M
Gross Margin
59.9%
Operating Margin
-1662.8%
Net Margin
-2433.9%
YoY Growth
N/A
EPS
$-0.27
Financial Flow
NRX Pharmaceuticals, Inc. Q3 2025 Financial Summary
NRX Pharmaceuticals, Inc. reported revenue of $242.0K for Q3 2025, with a net profit of $-5.9M (-2433.9% margin). Cost of goods sold was $97.0K, operating expenses totaled $4.2M.
Key Financial Metrics
| Total Revenue | $242.0K |
|---|---|
| Net Profit | $-5.9M |
| Gross Margin | 59.9% |
| Operating Margin | -1662.8% |
| Report Period | Q3 2025 |
Income Statement
| Q3 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $242000 |
| YoY Growth | N/A | N/A | N/A | N/A |
Balance Sheet
| Q3 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|
| Assets | $4.5M | $7.6M | $4.8M | $15.0M |
| Liabilities | $23.3M | $32.8M | $40.5M | $40.8M |
| Equity | $-18.8M | $-25.2M | $-35.6M | $-25.8M |
Cash Flow
| Q3 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|
| Operating CF | $-2.3M | $-3.5M | $-4.0M | $-2.9M |